ストックスクリーナーアプリを入手
2.72
5.23%
-0.15
アフターアワーズ：
2.68
-0.04
-1.47%
前日終値:
$2.87
開ける：
$2.87
24時間の取引高:
370.99K
Relative Volume:
0.39
時価総額：
$90.30M
収益：
-
当期純損益:
$-86.60M
株価収益率:
-0.9603
EPS:
-2.8324
ネットキャッシュフロー:
$-67.37M
1週間 パフォーマンス:
-3.55%
1か月 パフォーマンス:
-23.81%
6か月 パフォーマンス:
-66.95%
1年 パフォーマンス:
-83.05%
1日の値動き範囲:
$2.67
$2.889
1週間の範囲:
$2.5109
$3.08
52週間の値動き範囲:
$1.45
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
名前
Lexeo Therapeutics Inc
セクター
電話
(212) 547-9879
住所
345 PARK AVENUE SOUTH, NEW YORK
LXEO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
2.72 | 93.60M | 0 | -86.60M | -67.37M | -2.8324 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-06-06 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-28 | 開始されました | Chardan Capital Markets | Buy |
| 2023-11-28 | 開始されました | JP Morgan | Overweight |
| 2023-11-28 | 開始されました | Leerink Partners | Outperform |
| 2023-11-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-28 | 開始されました | Stifel | Buy |
すべてを表示
Lexeo Therapeutics Inc (LXEO) 最新ニュース
Lexeo Therapeutics (NASDAQ:LXEO) Given New $10.00 Price Target at JPMorgan Chase & Co. - Defense World
Leerink Partnrs Issues Optimistic Outlook for LXEO Earnings - Defense World
Lexeo Therapeutics (LXEO) Price Target Lowered by JP Morgan | LXEO Stock News - GuruFocus
BNP Paribas Financial Markets Buys 28,986 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo raises $80 million to shore up gene therapy work after layoffs - The Pharma Letter
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook - Investing.com Australia
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook By Investing.com - Investing.com India
Lexeo Therapeutics raises $80M in private placement (LXEO) - Seeking Alpha
Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing - marketscreener.com
Lexeo prices 20.8M shares at $2.8825 in private placement - TipRanks
Lexeo Therapeutics Announces $80M Private Placement Agreement - TipRanks
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | LXEO Stock News - GuruFocus
Lexeo Therapeutics secures $80 million in private placement By Investing.com - Investing.com India
Lexeo Therapeutics secures $80 million in private placement - Investing.com
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of ... - Bluefield Daily Telegraph
Major Investors Back Lexeo Therapeutics with $80M for Breakthrough Genetic Heart Disease Programs - Stock Titan
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Price T Rowe Associates Inc. MD Acquires New Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Q1 Earnings Forecast for LXEO Issued By HC Wainwright - Defense World
FY2025 Earnings Forecast for LXEO Issued By Chardan Capital - Defense World
HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $15.00 - Defense World
Lexeo stock price target cut to $15 by H.C. Wainwright - Investing.com South Africa
Lexeo Therapeutics price target lowered to $15 from $23 at H.C. Wainwright - TipRanks
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating - TipRanks
#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promise - Endpoints News
Lexeo Therapeutics (LXEO) Analyst Rating Update and Price Target Adjustment | LXEO Stock News - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Cut to $15 by H.C. Wainwr - GuruFocus
Leerink Partnrs Has Bearish Forecast for LXEO Q2 Earnings - Defense World
Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics: Strategic Focus and Promising Pipeline Drive Buy Rating - TipRanks
Lexeo Therapeutics (LXEO) Sees Price Target Adjustment by Charda - GuruFocus
Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
Lexeo Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan - TipRanks
Lexeo Trims 15% of Workforce, Shifts Focus to Lead Cardiac Programs - BioSpace
Lexeo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies - Fierce Biotech
Lexeo (LXEO) Projects Strong Financial Position and Clinical Adv - GuruFocus
Lexeo (LXEO) Projects Strong Financial Position and Clinical Advancements | LXEO Stock News - GuruFocus
Lexeo Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - The Manila Times
Lexeo Therapeutics Reports Positive Interim Data for LX2006 in Friedreich Ataxia Cardiomyopathy and Announces Upcoming Registrational Study Plans - Nasdaq
Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView
Lexeo Therapeutics reports Q1 EPS (99c), consensus (77c) - TipRanks
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Position Boosted by Barclays PLC - Defense World
Ratio Examination: Lexeo Therapeutics Inc (LXEO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Lexeo Therapeutics Inc (NASDAQ: LXEO) Still Pointing Downwards - Stocksregister
Lexeo Therapeutics Inc expected to post a loss of 78 cents a shareEarnings Preview - TradingView
Lexeo Therapeutics Inc (LXEO) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):